We also suggest that both IL-33 and adiponectin may be used to predict the occurrence of significant hyperinsulinemia in the initial part of the second phase of insulin secretion, as well as the inflammatory status in MS patients, instead of others markers, which are a well-known acute phase inflammatory markers. This evidence concerns the gene ADIPOQ and Hyperinsulinemia.